Quarterly report pursuant to Section 13 or 15(d)

Non-controlling Interest (Details)

v3.20.1
Non-controlling Interest (Details) - USD ($)
3 Months Ended
Sep. 05, 2018
Mar. 31, 2020
Mar. 31, 2019
Noncontrolling Interest      
Related Party Transaction, Expenses from Transactions with Related Party $ 441,000    
Research and Development Expense   $ 1,635,000 $ 2,418,000
SYN Biomics      
Noncontrolling Interest      
Equity interest by parent   83.00%  
Accumulated net loss attributable to the non-controlling interest   $ 2,900,000 2,900,000
Cedarssinai Medical Center [Member]      
Noncontrolling Interest      
Number Of Common Stock To Be Issued 50,000 50,000  
Research and Development Expense   $ 67,000 $ 16,000
Fair Value Of Shares Issued $ 285,000    
Cedarssinai Medical Center [Member] | SYN Biomics      
Noncontrolling Interest      
Additional Number Of Common Stock To Be Issued 2,420,000    
Number Of Common Stock To Be Held By Related Party 7,480,000    
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 17.00%